Storm Therapeutics

Storm Therapeutics is a clinical-stage biotechnology company that discovers and develops small-molecule therapies.

Health and bio

Latest funding

$56M Series B+ · April 16, 2026

Source: fundraisingfox.com

Total raised: $102.06M across 3 sourced rounds

All 3 rounds ↓

Website: stormtherapeutics.com.

X: @storm_tx · 970 followers.

LinkedIn: storm-therapeutics-limited.

Category: Health and bio.

Sectors: Biotechnology, Health Care, Medical, Therapeutics.

Stage: Series B+.

Based in: Cambridge, United Kingdom.

Total raised: $102.06M in 3 sourced rounds.

Last round: Apr 16, 2026 · 213 days ago.

Headcount: 11–50 employees.

On Recent Funding since: Sep 29, 2026.

Signals

X account@storm_tx · created Jun 15, 2016 (10 years old) · 970 followers

Website registeredMay 27, 2016 (10 years old)

About Storm Therapeutics

It focuses on RNA-modifying enzymes to treat cancer and other diseases. Its lead product, STC-15, is an inhibitor of the RNA-modifying enzyme METTL3 and is being evaluated in clinical studies for various cancers.

TIMELINE · MONEY RAISED

Storm Therapeutics | 32 days from website to first raise on record

@storm_tx·Raised $102M in 3 sourced rounds·2 signals before the first raise

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

Date	Round	Amount	Lead	Source
Apr 16, 2026	Series B+	$56M	—	fundraisingfox.com
Dec 14, 2022	Series B+	$30M	CCambridge Innovation Capital	finsmes.com
Jun 28, 2016	Series A	$16.06M	—	m-ventures.com

Timeline

June 15, 2016
X account created
May 27, 2016
Website created

Founders and team

EM
Eric Miska Founder

@ericmiska · LinkedIn
TK
Tony Kouzarides Founder

LinkedIn
GM
Gerald McMahon CEO and President
AA
Atif Abbas Chief Medical Officer
EM
Eric Martin Chief Development Officer
MH
Marguerite Hutchinson Chief Business Officer

Investors

Companies like Storm Therapeutics

CCellCentric$220M Series B+ · May 2026
AAlzheon$100M Series B+ · Apr 2022
GGrannus Therapeutics
AAlpha-9 Oncology$175M Series B+ · Oct 2024
RRevier Therapeutics$6.95M Seed · Aug 2026
AAlvara TherapeuticsPre Seed · Sep 2026

Other companies backed by Cambridge Innovation Capital

TT-Therapeutics$133M Series B+ · Nov 2026
MMicrobiotica$47.69M Series B+ · Oct 2026
SSalience Labs$125M Series B+ · Oct 2026
CCMR Surgical$400M Series B+ · Oct 2026
TTRIMTECH Therapeutics$14M Seed · Jun 2026
TTrent AI$13M Seed · Apr 2026

Cambridge Innovation Capital portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/storm-therapeutics (get a free API key).